

.....  
(Original Signature of Member)

115TH CONGRESS  
2D SESSION

**H. R.** \_\_\_\_\_

To amend the Federal Food, Drug, and Cosmetic Act to authorize the Secretary of Health and Human Services to consider the potential for misuse and abuse when determining whether to approve certain drugs, and for other purposes

\_\_\_\_\_  
IN THE HOUSE OF REPRESENTATIVES

M\_\_\_\_. \_\_\_\_\_ introduced the following bill; which was referred to the  
Committee on \_\_\_\_\_

\_\_\_\_\_  
**A BILL**

To amend the Federal Food, Drug, and Cosmetic Act to authorize the Secretary of Health and Human Services to consider the potential for misuse and abuse when determining whether to approve certain drugs, and for other purposes

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

1 **SECTION 1. CONSIDERATION OF POTENTIAL FOR MISUSE**  
2 **AND ABUSE REQUIRED FOR DRUG AP-**  
3 **PROVAL.**

4 (a) IN GENERAL.—Section 505(d) of the Federal  
5 Food, Drug, and Cosmetic Act (21 U.S.C. 355(d)) is  
6 amended—

7 (1) in the first sentence—

8 (A) by striking “or (7)” and inserting  
9 “(7)”; and

10 (B) by inserting before the period at the  
11 end the following: “; or (8) if the drug is or  
12 contains a controlled substance for which a list-  
13 ing in any schedule is in effect (on a temporary  
14 or permanent basis) under section 201 of the  
15 Controlled Substances Act, upon the basis of in-  
16 formation submitted to him as part of the ap-  
17 plication, or upon the basis of any other infor-  
18 mation before him with respect to such drug,  
19 the drug is unsafe for use due to the risks of  
20 abuse or misuse or there is insufficient informa-  
21 tion to show that the drug is safe for use con-  
22 sidering such risks”; and

23 (2) in the second sentence, by striking “(6)”  
24 and inserting “(6) and (8)”.

1 (b) WITHDRAWAL AUTHORITY.—Section 505(e) of  
2 the Federal Food, Drug, and Cosmetic Act (21 U.S.C.  
3 355(e)) is amended in the first sentence—

4 (1) by striking “or (5)” and inserting “(5)”;

5 and

6 (2) by inserting the following: “; or (6) that, in  
7 the case of a drug that is or contains a controlled  
8 substance for which a listing in any schedule is in  
9 effect (on a temporary or permanent basis) under  
10 section 201 of the Controlled Substances Act, on the  
11 basis of new information before him with respect to  
12 such drug, evaluated together with the information  
13 available to him when the application was approved,  
14 that the drug is unsafe for use due to the risks of  
15 abuse or misuse” after “material fact”.

16 (c) RULE OF CONSTRUCTION.—Nothing in the  
17 amendments made by this section shall be construed to  
18 limit or narrow, in any manner, the meaning or applica-  
19 tion of the provisions of paragraphs (1) through (5) of  
20 section 505(d) of the Federal Food, Drug, and Cosmetic  
21 Act (21 U.S.C. 355(d)) or paragraphs (1) and (2) of sec-  
22 tion 505(e) of such Act (21 U.S.C. 355(e)).